Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genomic Analysis of Human Brain Metastases Treated with Stereotactic Radiosurgery Reveals Unique Signature Based on Treatment Failure. [WES]

ABSTRACT: Genomic Analysis of Human Brain Metastases Treated with Stereotactic Radiosurgery Reveals Unique Signature Based on Treatment Failure. [WES]

PROVIDER: PRJNA1080558 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR28559700_1.fastq.gz	Fastqsanger.gz
	SRR28559700_2.fastq.gz	Fastqsanger.gz
	SRR28559636_1.fastq.gz	Fastqsanger.gz
	SRR28559636_2.fastq.gz	Fastqsanger.gz
	SRR28559637_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 131

Similar Datasets

Genomic Analysis of Human Brain Metastases Treated with Stereotactic Radiosurgery Reveals Unique Signature Based on Treatment Failure. [WES]

Project description:Stereotactic radiosurgery (SRS) has been shown to be efficacious for treatment of limited brain metastasis (BM), however, the effects of SRS on human brain metastases have yet to be studied. We performed genomic analysis of resected brain metastases from patients whose resected lesion was previously treated with SRS. Our analyses demonstrated for the first time that patients possess a distinct genomic signature based on type of treatment failure including local failure, leptomeningeal spread, and radio-necrosis. Examination of the center and peripheral edge of the tumors treated with SRS indicated differential DNA damage distribution and an enrichment for tumor suppressor mutations and DNA damage repair pathways along the peripheral edge. Furthermore, the two clinical modalities used to deliver SRS, LINAC and GK, demonstrated differential effects on the tumor landscape even between controlled primary sites. Our study provides, in humans, biological evidence of differential effects of SRS across BM’s.

2024-03-21 | GSE259267 | GEO

Genomic Analysis of Human Brain Metastases Treated with Stereotactic Radiosurgery Reveals Unique Signature Based on Treatment Failure. [RNA-Seq]

2024-03-21 | GSE256463 | GEO

Genomic Analysis of Human Brain Metastases Treated with Stereotactic Radiosurgery Reveals Unique Signature Based on Treatment Failure.

Project description:Genomic Analysis of Human Brain Metastases Treated with Stereotactic Radiosurgery Reveals Unique Signature Based on Treatment Failure.

| PRJNA1081304 | ENA

Genomic Analysis of Human Brain Metastases Treated with Stereotactic Radiosurgery Reveals Unique Signature Based on Treatment Failure. [RNA-Seq]

Project description:Genomic Analysis of Human Brain Metastases Treated with Stereotactic Radiosurgery Reveals Unique Signature Based on Treatment Failure. [RNA-Seq]

| PRJNA1079731 | ENA

RNA/WES/ATAC/scRNA sequencing of murine melanoma primary and LN metastases

Project description:The purpose of this study is to identify transcriptional, mutational, andepigenetic differences between LN metastases from primary tumors. Using in vivo serial passaging of the minimally metastatic syngeneic murine melanoma cell line B16-F0, we have generated nearly 300 unique cell lines spanning nine generations of in vivo passaging, derived from LNs, and exhibiting varying degrees of metastatic potential to LNs. Here, we perform mRNAseq on 30 of the lines representing a range of anatomical locations (distinct LNs), generations, and phylogenetic lineages. The subsequent differential expression analysis reveals a marked upregulation of immune-related genes. Additionally, we perform WES to identify differences in particular mutations, total mutational burden, and predicted neoantigen burden. Additionally, we perform ATAC-seq to assess changes in chromatin accessibility hat correlate with LN metastasis. We also perform scRNA-seq on dissociated LNs from mice with and without LN metastases.

2021-06-14 | GSE117529 | GEO

RNA/WES/ATAC/scRNA sequencing of murine melanoma primary and LN metastases

Project description:RNA/WES/ATAC/scRNA sequencing of murine melanoma primary and LN metastases

| PRJNA482417 | ENA

Genomic Analysis of Human Brain Metastases Treated with Stereotactic Radiosurgery Reveals Unique Signature Based on Treatment Failure.

Project description:This SuperSeries is composed of the SubSeries listed below.

2024-03-21 | GSE259343 | GEO

Genomic analysis of human brain metastases treated with stereotactic radiosurgery reveals unique signature based on treatment failure

Project description: Not available

| S-EPMC11016778 | biostudies-literature

p53 dimers elicit unique tumor suppressive activities through an altered metabolic program [WES]

Project description:p53 dimers elicit unique tumor suppressive activities through an altered metabolic program [WES]

| PRJNA912181 | ENA

Proteogenomics of colorectal cancer liver metastases

Project description:Colorectal cancer (CRC) is the third most common and second most deadly cancer worldwide. Treatments for metastatic CRC (mCRC) are still largely based on toxic chemotherapy regimens, but important insights into tumor biology enabled the development of targeted cancer therapies. Here, we describe a proteogenomic analysis of CRC liver metastases (metastatic CRC, mCRC), an ideal setting to analyze therapeutic resistance which occurs in a short time frame. We selected liver metastases from two CRC patients on both of which we performed deep proteome profiling and WES and RNAseq-directed database searches, identifying 10 predicted muttaions, one of which was KRAS G12V. finding we generated targeted parallel reaction monitoring (PRM) assays using stable isotope labelled standard (SIS) peptides to quantify the actual concentration (fmol per µg of total protein) of the mutated and canonical (wildtype) protein variants for 8 different mutations. We demonstrate on a total of 8 tumor and 6 paired healthy tissue samples (7 and 6 out of these KRASG12V) that PRM allows quantifying the actual mutation rate on the protein level from as little 10 µg of total protein starting amount and within a single 1 hour nano-LC-MS/MS run.

2019-12-04 | PXD014222 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data